Myricx Bio
A UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.
Myricx is advancing a pipeline of ADCs based on its novel NMT inhibitor (NMTi) payload chemistry platform to address serious unmet needs in oncology. The company's proprietary ADCs have demonstrated compelling preclinical efficacy and safety across multiple solid tumor-associated antigens and specific cancer cell types.
Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Sofinnova Partners and Brandon Capital Partners.
Latest Myricx Bio News & Features
28 November 2023
21 November 2023
13 September 2023
8 September 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze